129 related articles for article (PubMed ID: 28177983)
1. The contribution of transgenic and nontransgenic animal models in Alzheimer's disease drug research and development.
Mhillaj E; Cuomo V; Mancuso C
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):95-111. PubMed ID: 28177983
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic strategies and Alzheimer's disease: contribution of animal models].
Chabrier PE
Ann Pharm Fr; 2009 Mar; 67(2):97-103. PubMed ID: 19298893
[TBL] [Abstract][Full Text] [Related]
3. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications.
Sabbagh JJ; Kinney JW; Cummings JL
Neurobiol Aging; 2013 Jan; 34(1):169-83. PubMed ID: 22464953
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches to models of Alzheimer's disease pathology for drug screening and development.
Shaughnessy L; Chamblin B; McMahon L; Nair A; Thomas MB; Wakefield J; Koentgen F; Ramabhadran R
J Mol Neurosci; 2004; 24(1):23-32. PubMed ID: 15314246
[TBL] [Abstract][Full Text] [Related]
5. Rodent models for Alzheimer's disease drug discovery.
Puzzo D; Gulisano W; Palmeri A; Arancio O
Expert Opin Drug Discov; 2015 Jul; 10(7):703-11. PubMed ID: 25927677
[TBL] [Abstract][Full Text] [Related]
6. The treatment of Alzheimer's disease using Chinese medicinal plants: from disease models to potential clinical applications.
Su Y; Wang Q; Wang C; Chan K; Sun Y; Kuang H
J Ethnopharmacol; 2014 Mar; 152(3):403-23. PubMed ID: 24412377
[TBL] [Abstract][Full Text] [Related]
7. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models.
Reddy PH; McWeeney S
Neurobiol Aging; 2006 Aug; 27(8):1060-77. PubMed ID: 16157420
[TBL] [Abstract][Full Text] [Related]
8. Nanotherapeutic strategies for the treatment of Alzheimer's disease.
Gu X; Chen H; Gao X
Ther Deliv; 2015 Feb; 6(2):177-95. PubMed ID: 25690086
[TBL] [Abstract][Full Text] [Related]
9. Animal models of amyloid-beta-related pathologies in Alzheimer's disease.
Philipson O; Lord A; Gumucio A; O'Callaghan P; Lannfelt L; Nilsson LN
FEBS J; 2010 Mar; 277(6):1389-409. PubMed ID: 20136653
[TBL] [Abstract][Full Text] [Related]
10. Mechanical stress models of Alzheimer's disease pathology.
Levy Nogueira M; Epelbaum S; Steyaert JM; Dubois B; Schwartz L
Alzheimers Dement; 2016 Mar; 12(3):324-33. PubMed ID: 26718585
[TBL] [Abstract][Full Text] [Related]
11. Cardiolipin profile changes are associated to the early synaptic mitochondrial dysfunction in Alzheimer's disease.
Monteiro-Cardoso VF; Oliveira MM; Melo T; Domingues MR; Moreira PI; Ferreiro E; Peixoto F; Videira RA
J Alzheimers Dis; 2015; 43(4):1375-92. PubMed ID: 25182746
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
[TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease.
Giménez-Llort L; Ratia M; Pérez B; Camps P; Muñoz-Torrero D; Badia A; Clos MV
Behav Pharmacol; 2017 Apr; 28(2 and 3-Spec Issue):124-131. PubMed ID: 28125507
[TBL] [Abstract][Full Text] [Related]
14. [Alzheimer's disease: new prospects in therapy and applied experimental models].
Kubis AM; Janusz M
Postepy Hig Med Dosw (Online); 2008 Aug; 62():372-92. PubMed ID: 18688208
[TBL] [Abstract][Full Text] [Related]
15. Lamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model.
Wang K; Fernandez-Escobar A; Han S; Zhu P; Wang JH; Sun Y
Biomed Res Int; 2016; 2016():7810196. PubMed ID: 28042572
[TBL] [Abstract][Full Text] [Related]
16. Neurochemical basis for symptomatic treatment of Alzheimer's disease.
Francis PT; Ramírez MJ; Lai MK
Neuropharmacology; 2010; 59(4-5):221-9. PubMed ID: 20156462
[TBL] [Abstract][Full Text] [Related]
17. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model.
Cheng XR; Zhou WX; Zhang YX
Ageing Res Rev; 2014 Jan; 13():13-37. PubMed ID: 24269312
[TBL] [Abstract][Full Text] [Related]
18. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
[TBL] [Abstract][Full Text] [Related]
19. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid.
Giménez-Llort L; Blázquez G; Cañete T; Johansson B; Oddo S; Tobeña A; LaFerla FM; Fernández-Teruel A
Neurosci Biobehav Rev; 2007; 31(1):125-47. PubMed ID: 17055579
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of an aged onset model of Alzheimer's disease in Drosophila melanogaster.
Mhatre SD; Michelson SJ; Gomes J; Tabb LP; Saunders AJ; Marenda DR
Exp Neurol; 2014 Nov; 261():772-81. PubMed ID: 25173219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
